Skip to content

Released Aug 5, 2020, after the close

10-Q filed Aug 5, 2020, 36 days after period end · 0001564590-20-036859

Q2 2020 · 10-Q
Revenue$39.38M+1,178.4% vs Q2 2019+864.9% vs Q1 2020
Net Income$7.27MN/M vs Q2 2019N/M vs Q1 2020
EPS Diluted$0.19N/M vs Q2 2019N/M vs Q1 2020
Operating Income$6,579,000N/M
Operating Cash Flowderived-$23,116,000N/M
Free Cash Flowderived-$23,521,000N/M
Margins · derived
Operating margin16.7%+656.3 pt vs Q2 2019
Net margin18.5%+619.2 pt vs Q2 2019

What the release said

The release

Same quarter

MetricQ2 2020Q2 2019Q2 2018Q2 2017
Revenue$39.38M$3.08M$3.22M$2.36M
Net Income$7.27M-$18.50M-$26.81M-$13.60M
EPS Diluted$0.19-$0.72-$1.30-$780.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR